Prime Medicine, Inc. financial data

Symbol
PRME on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
60 First St., Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 508 % -43.8%
Debt-to-equity 30.9 % +14.1%
Return On Equity -113 % -15.3%
Return On Assets -86.6 % -68.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 120M shares +23.4%
Common Stock, Shares, Outstanding 120M shares +23.4%
Entity Public Float 603M USD
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 119M shares +31.7%
Weighted Average Number of Shares Outstanding, Diluted 119M shares +31.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 43.1M USD +24.5%
General and Administrative Expense 47.3M USD +31.3%
Operating Income (Loss) -224M USD -43.6%
Nonoperating Income (Expense) 5.97M USD +17.7%
Income Tax Expense (Benefit) -108K USD +25.5%
Net Income (Loss) Attributable to Parent -217M USD -44.6%
Earnings Per Share, Basic -2.17 USD/shares -23.3%
Earnings Per Share, Diluted -2.17 USD/shares -23.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 55.6M USD -53.9%
Cash, Cash Equivalents, and Short-term Investments 163M USD -21.5%
Other Assets, Current 3.74M USD
Assets, Current 171M USD -21.8%
Property, Plant and Equipment, Net 23.8M USD +15.8%
Operating Lease, Right-of-Use Asset 51.6M USD +94.7%
Other Assets, Noncurrent 0 USD -100%
Assets 260M USD -7.53%
Accounts Payable, Current 4.64M USD -15.5%
Employee-related Liabilities, Current 4.99M USD
Accrued Liabilities, Current 10.9M USD
Liabilities, Current 20.7M USD -27.8%
Deferred Income Tax Liabilities, Net 134K USD +74%
Operating Lease, Liability, Noncurrent 36.4M USD +205%
Liabilities 63.1M USD +54.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -71K USD +73.5%
Retained Earnings (Accumulated Deficit) -592M USD -58%
Stockholders' Equity Attributable to Parent 197M USD -18.1%
Liabilities and Equity 260M USD -7.53%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -67.7M USD -62.9%
Net Cash Provided by (Used in) Financing Activities 157M USD
Net Cash Provided by (Used in) Investing Activities -37M USD -192%
Common Stock, Shares Authorized 775M shares 0%
Common Stock, Shares, Issued 120M shares +23.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 52.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 69.1M USD -48.5%
Deferred Tax Assets, Valuation Allowance 119M USD +91.9%
Deferred Tax Assets, Gross 123M USD +74.3%
Operating Lease, Liability 41.6M USD +63.4%
Payments to Acquire Property, Plant, and Equipment 2.32M USD +16.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -217M USD -44.3%
Lessee, Operating Lease, Liability, to be Paid 203M USD +635%
Property, Plant and Equipment, Gross 34.1M USD +33.6%
Operating Lease, Liability, Current 5.22M USD -61.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 21.3M USD +445%
Lessee, Operating Lease, Liability, to be Paid, Year One 18.6M USD +24.2%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure +40.7%
Deferred Income Tax Expense (Benefit) 134K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31.4M USD +1362%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.8M USD +1137%
Deferred Tax Assets, Operating Loss Carryforwards 36M USD +76.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 20.9M USD +3578%
Additional Paid in Capital 789M USD +28.2%
Depreciation, Depletion and Amortization 5.34M USD +45.4%
Share-based Payment Arrangement, Expense 21.9M USD +137%